|
SEC File
Number: 0-54296
|
|
CUSIP
Number: 05463V 100
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one):
[
] Form 10-K[
] Form 20-F[
] Form 11-K [X] Form 10-Q[
] Form 10-D[ ] Form N-SAR
For Period Ended: March 31, 2022
|
[ ]
|
Transition Report on Form 10-K
|
|
[ ]
|
Transition Report on Form 20-F
|
|
[ ]
|
Transition Report on Form 11-K
|
|
[ ]
|
Transition Report on Form 10-Q
|
|
[ ]
|
Transition Report on Form N-SAR
|
For the Transition Period Ended:
|
Read Instruction (on back page) Before Preparing Form. Please
Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
|
Full
Name of Registrant:
|
Axim Biotechnologies, Inc.
|
|
Former Name if Applicable:
|
|
|
Address of Principal Executive Office (Street and Number):
|
6191 Cornerstone Court, E., Suite 114
|
|
City, State and Zip Code:
|
San Diego, CA 92121
|
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
|
[
X ]
|
(a)
|
The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|
|
(b)
|
The subject annual report, semi-annual report, transition report on
Forms 10-K, 20-F, 11- K, Form N-SAR, or Form N-CSR or portion
thereof, will be filed on or before the 15th calendar day following
the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due
date; and
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
PART III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 11-K, 10-Q,
10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period.
The Company is unable to file, without unreasonable effort or
expense, its Quarterly Report on Form 10-Q for the period ending
March 31, 2022 (the “Form 10-Q”). Additional time is needed for the
Company’s independent registered public accounting firm to complete
its review of the unaudited financial statements included in the
Form 10-Q and for the Company to provide additional information to
its accountants and auditors in order to produce a complete,
accurate Quarterly Report. Additionally, the Company seeks an
extension to finalize the narrative of the Form 10-Q so that it
will properly inform investors and the public of the Company’s
actions for the Quarter ended March 31, 2022. The Company
anticipates on filing its Form 10-Q on or by May 23, 2022.
PART IV - OTHER INFORMATION
(1)Name
and telephone number of person to contact in regard to this
notification:
|
John W. Huemoeller II
|
|
(858) 923-4422
|
|
(Name)
|
|
(Area Code) (Telephone number)
|
(2)Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (or for such
shorter) period that the registrant was required to file such
reports) been filed? If answer is no, identify report(s):
[X] Yes [ ] No
(3)Is
it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof:
[ ] Yes [X] No
If so,
attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
AXIM Biotechnologies, Inc.
|
|
(Name of Registrant as Specified in Charter)
|
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date: May 16, 2022
|
|
/s/ John W. Huemoeller II
|
|
|
|
John W. Huemoeller
II President
|
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name
and title of the person signing the form shall be typed or printed
beneath the signature. If the statement is signed on behalf of the
registrant by an authorized representative (other than an executive
officer), evidence of the representative’s authority to sign on
behalf of the registrant shall be filed with the form.